BRPI0911958A2 - formas de dosagem administráveis oralmente compreendendo angiogenina e usos das mesmas - Google Patents

formas de dosagem administráveis oralmente compreendendo angiogenina e usos das mesmas

Info

Publication number
BRPI0911958A2
BRPI0911958A2 BRPI0911958A BRPI0911958A BRPI0911958A2 BR PI0911958 A2 BRPI0911958 A2 BR PI0911958A2 BR PI0911958 A BRPI0911958 A BR PI0911958A BR PI0911958 A BRPI0911958 A BR PI0911958A BR PI0911958 A2 BRPI0911958 A2 BR PI0911958A2
Authority
BR
Brazil
Prior art keywords
angiogenin
dosage forms
orally administrable
administrable dosage
orally
Prior art date
Application number
BRPI0911958A
Other languages
English (en)
Inventor
Angus Tester
Benjamin Cocks
Matthew Mcdonagh
Peter Hobman
Original Assignee
Agriculture Victoria Serv Pty
Murray Goulburn Coop Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008902371A external-priority patent/AU2008902371A0/en
Application filed by Agriculture Victoria Serv Pty, Murray Goulburn Coop Co Ltd filed Critical Agriculture Victoria Serv Pty
Publication of BRPI0911958A2 publication Critical patent/BRPI0911958A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911958A 2008-05-14 2009-05-14 formas de dosagem administráveis oralmente compreendendo angiogenina e usos das mesmas BRPI0911958A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008902371A AU2008902371A0 (en) 2008-05-14 Oral preparation
PCT/AU2009/000602 WO2009137879A1 (en) 2008-05-14 2009-05-14 Orally administrable dosage forms comprising angiogenin and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0911958A2 true BRPI0911958A2 (pt) 2015-10-13

Family

ID=41318285

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911958A BRPI0911958A2 (pt) 2008-05-14 2009-05-14 formas de dosagem administráveis oralmente compreendendo angiogenina e usos das mesmas

Country Status (14)

Country Link
US (1) US20110262422A1 (pt)
EP (1) EP2307044A4 (pt)
JP (1) JP2011519960A (pt)
KR (1) KR20110033122A (pt)
CN (1) CN102099050A (pt)
AU (1) AU2009246052A1 (pt)
BR (1) BRPI0911958A2 (pt)
CA (1) CA2724048A1 (pt)
IL (1) IL209284A0 (pt)
MX (1) MX2010012438A (pt)
NZ (1) NZ589306A (pt)
RU (1) RU2010150934A (pt)
WO (1) WO2009137879A1 (pt)
ZA (1) ZA201009004B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723987C (en) 2008-05-14 2019-06-11 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
WO2011060489A1 (en) * 2009-11-18 2011-05-26 Murray Goulburn Co-Operative Co. Limited Transgenic non-human animals
EP2501411A4 (en) * 2009-11-18 2013-07-03 Murray Goulburn Coop Co Ltd PROCESS FOR IMPROVED ORAL ADMINISTRATION
JP2013511261A (ja) * 2009-11-18 2013-04-04 マリー ゴールバーン シーオー−オペレイティブ シーオー．リミテッド 組換え微生物
WO2011113100A1 (en) * 2010-03-17 2011-09-22 Murray Goulburn Co-Operative Co. Limited Method of treating a bone disorder
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
MX2015001345A (es) * 2012-07-31 2015-09-04 Megmilk Snow Brand Co Ltd Bebida y metodo para preparar la misma.
US9522178B2 (en) 2012-07-31 2016-12-20 Megmilk Snow Brand Co., Ltd. Powdered milk product and method for producing the same
JP6203723B2 (ja) * 2012-07-31 2017-09-27 雪印メグミルク株式会社 骨疾患の予防又は治療用タンパク質素材及びその製造方法
CA2879952C (en) * 2012-07-31 2019-09-03 Megmilk Snow Brand Co., Ltd. Novel fermented milk product and method for producing the same
DK2880997T3 (da) * 2012-07-31 2019-07-29 Megmilk Snow Brand Co Ltd Drik og fremgangsmåde til fremstilling deraf
US9629878B2 (en) 2012-07-31 2017-04-25 Megmilk Snow Brand Co., Ltd. Fermented milk product and method for producing the same
WO2014020683A1 (ja) * 2012-07-31 2014-02-06 雪印メグミルク株式会社 チーズ類及びその製造方法
CA2879995C (en) * 2012-07-31 2019-09-03 Megmilk Snow Brand Co., Ltd. Novel powdered milk product and method for producing the same
CN104507334B (zh) 2012-07-31 2016-11-16 雪印惠乳业株式会社 新蛋白材料
JP2016152809A (ja) * 2016-04-05 2016-08-25 雪印メグミルク株式会社 飲料及びその製造方法
JP6562956B2 (ja) * 2017-02-28 2019-08-21 雪印メグミルク株式会社 飲料及びその製造方法
JP6357265B2 (ja) * 2017-06-07 2018-07-11 雪印メグミルク株式会社 骨疾患の予防又は治療用タンパク質素材
JP6357266B2 (ja) * 2017-06-07 2018-07-11 雪印メグミルク株式会社 骨疾患の予防又は治療用タンパク質素材

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2947657B2 (ja) * 1991-02-27 1999-09-13 森永乳業株式会社 神経成長因子産生促進剤
JP3929088B2 (ja) * 1996-06-20 2007-06-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
JPH10139682A (ja) * 1996-11-14 1998-05-26 Mitsubishi Chem Corp 骨吸収促進剤
CN1761463A (zh) * 2003-03-17 2006-04-19 日本烟草产业株式会社 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法
JP4698935B2 (ja) * 2003-05-07 2011-06-08 雪印乳業株式会社 皮膚コラーゲン産生促進剤
WO2004106491A2 (en) * 2003-05-22 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Angiogenin-based hiv-1 therapies
WO2005072764A2 (en) * 2004-01-16 2005-08-11 Novocell, Inc. Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
WO2007023479A2 (en) * 2005-08-23 2007-03-01 Royal College Of Surgeons In Ireland Treatment of central nervous system injury
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US20070275036A1 (en) * 2006-05-18 2007-11-29 Celldyne Biopharma, Llc Avian follistatin product
CA2702645C (en) * 2006-11-10 2018-01-02 Agriculture Victoria Services Pty Ltd Process for the preparation of angiogenin
CA2723987C (en) * 2008-05-14 2019-06-11 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders

Also Published As

Publication number Publication date
CA2724048A1 (en) 2009-11-19
MX2010012438A (es) 2011-06-20
JP2011519960A (ja) 2011-07-14
AU2009246052A1 (en) 2009-11-19
CN102099050A (zh) 2011-06-15
WO2009137879A1 (en) 2009-11-19
EP2307044A4 (en) 2011-10-05
EP2307044A1 (en) 2011-04-13
IL209284A0 (en) 2011-01-31
US20110262422A1 (en) 2011-10-27
ZA201009004B (en) 2012-05-30
RU2010150934A (ru) 2012-06-20
KR20110033122A (ko) 2011-03-30
NZ589306A (en) 2012-11-30

Similar Documents

Publication Publication Date Title
BRPI0911958A2 (pt) formas de dosagem administráveis oralmente compreendendo angiogenina e usos das mesmas
NO2023015I1 (no) Benzovindiflupyr and Difenoconazole
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
BRPI0908864A2 (pt) formas da rifaximina e usos das mesmas
SMT201500177B (it) Combinazione terapeutica comprendente dolutegravir, abacavir e lamivudina
BRPI1016199A2 (pt) cobertura de ferimento e kit de tratamento de ferimentos.
BRPI1008709A2 (pt) composições e usos das mesmas.
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0920216A2 (pt) forma de dosagem intraoral em múltiplas porções e uso das mesmas
BRPI0810814A2 (pt) Formas sólidas de dosagem incluindo tadalafil
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
BRPI1010739A2 (pt) formas de dosagens de apixaban.
BR112012013148A2 (pt) formulação farmacêutica e uso
BR112012002114A2 (pt) cevadas e seu usos.
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BRPI0910925A2 (pt) conjuntos de transferência de líquido e métodos relacionados
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
IT1403751B1 (it) Rullo portacingoli con distanziatori sferici interni
FI20075881L (fi) Lääketieteellinen väline ja sen valmistus
BRPI0922804A8 (pt) formas de dosagem sólidas de bendamustina
BRPI1015941A2 (pt) formulações de comprimido de 3-cianoquinolina e uso das mesmas.
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
BRPI0922806A2 (pt) formas de dosagem oral de bendamustina
EP2197448A4 (en) dosing schedule
BRPI0811511A2 (pt) Paliperidona pura e processos para sua preparação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements